Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD) announced that CEO George Magrath, M.D. will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 8:15 a.m. PT.
The company is a clinical-stage biopharmaceutical developer of gene therapies for inherited retinal diseases. A live and archived webcast will be available on Opus Genetics' investor website under Events.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IRD declined 2.40%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IRD is up 4.6% while close biotech peers show mixed moves (e.g., ATRA +7.54%, ANEB -1.38%), indicating today’s strength appears more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Clinical safety update | Positive | +4.4% | IDMC issued positive safety recommendation to continue BEST1 Phase 1/2 trial. |
| Dec 02 | Inducement grants | Neutral | -0.5% | Equity inducement awards to new employees under Nasdaq Rule 5635(c)(4). |
| Nov 20 | Conference participation | Neutral | +3.8% | Management scheduled for BTIG Ophthalmology Day and Piper Sandler conference. |
| Nov 13 | First-patient dosing | Positive | -3.6% | First participant dosed in OPGx-BEST1 Phase 1/2 gene therapy trial. |
| Nov 12 | Earnings & update | Positive | -2.5% | Q3 2025 results and positive LCA5 data with extended cash runway. |
Positive clinical or strategic updates often saw aligned gains, while some major clinical and earnings milestones showed negative price divergence.
This announcement follows several catalysts over the past month. On Nov 12, 2025, IRD reported Q3 2025 results with over $50M cash post-raise and clinical progress in OPGx-LCA5 and OPGx-BEST1. Subsequent news included dosing the first OPGx-BEST1 Phase 1/2 participant on Nov 13, participation in investor conferences on Nov 20, and an inducement equity grant on Dec 2. A Dec 9 IDMC review for the BEST1 trial gave a positive safety recommendation. Today’s JPM conference presentation continues this investor-engagement trajectory.
Market Pulse Summary
This announcement highlights Opus Genetics’ plans to present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026 at 8:15 a.m. PT, extending a pattern of active investor outreach following recent clinical and financial updates. Prior news included positive BEST1 safety review, progress in OPGx-LCA5, and strengthened cash resources. Investors may focus on how conference remarks elaborate on clinical timelines, funding runway, and strategic priorities for the inherited retinal disease gene therapy portfolio.
AI-generated analysis. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases, announced today that George Magrath, M.D., Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 8:15 a.m. PT.
A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases. The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, RDH12, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
FAQ
When will Opus Genetics (IRD) present at the J.P. Morgan 2026 Healthcare Conference?
Who is presenting for Opus Genetics (IRD) at the January 15, 2026 conference?
Where can investors watch the Opus Genetics (IRD) J.P. Morgan presentation?
What is Opus Genetics' (IRD) business focus mentioned for the J.P. Morgan 2026 appearance?
Will the Opus Genetics (IRD) webcast from J.P. Morgan be archived for later viewing?
How can I find the Opus Genetics (IRD) webcast link for the J.P. Morgan 2026 presentation?
